第一章 总则 第一条 为规范威海百合生物技术股份有限公司（以下简称"公司"）的信 息披露行为，确保公司信息披露真实、准确、完整、及时、公平，根据《上市公 司信息披露管理办法》、《上市公司治理准则》、《上海证券交易所股票上市规则》 （以下简称"《上市规则》"）、《上海证券交易所上市公司自律监管指引第 2 号——信息披露事务管理》（以下简称"《指引》"）等法律、法规、规范性文 件及《威海百合生物技术股份有限公司章程》（以下简称"公司章程"）的有关 规定，制定本制度。 第二章 信息披露的基本原则 第二条 本制度所称"信息披露义务人"，是指公司及公司董事、高级管理 人员、股东、实际控制人，收购人，重大资产重组、再融资、重大交易有关各方 等自然人、单位及其相关人员，破产管理人及其成员，以及法律、行政法规和中 国证券监督管理委员会（以下简称"中国证监会"）规定的其他承担信息披露义 务的主体。 第三条 本制度所称信息披露，是指将所有对公司证券及其衍生品种交易 价格已经或可能产生重大影响或影响投资者作出价值判断和投资决策的信息，在 规定时间内，通过指定的媒体，以规定的方式向社会公众公布。 第四条 本制度所称的信息披露直通车（ ...

威海百合生物技术股份有限公司 内部审计制度 第一章 总则 第一条 为建立健全威海百合生物技术股份有限公司（以下简称"公司"） 内部审计制度，加强公司内部审计监督，保障公司财务管理、会计核算和生产经 营符合国家各项法律法规要求，根据《中华人民共和国公司法》、《中华人民共和 国审计法》、《审计署关于内部审计工作的规定》等法律、法规、规范性文件及《威 海百合生物技术股份有限公司章程》（以下简称"公司章程"）的有关规定，制定 本制度。 第二条 公司审计部是公司内部审计的实施机构，负责对公司内部控制制 度的建立和实施、公司财务信息的真实性和完整性等情况进行检查监督；审计部 配置若干内部审计人员（以下简称"审计人员"）从事内部审计工作。 第三条 公司全资、控股子公司（以下合称"子公司"）的内部审计工作参 照本制度执行。 第七条 公司各内部机构或职能部门、子公司以及具有重大影响的参股公 司应当配合审计部依法履行职责，不得妨碍审计部的工作。 第二章 责任机构及其职权 第四条 公司审计部为负责内部审计的职能部门，对董事会审计委员会负 责，向董事会审计委员会报告工作。内部审计机构在监督检查过程中，应当接受 审计委员会的监督指导。 ...

Summary of Key Points Core Viewpoint - A total of 18 companies have raised their share repurchase price limits since July, reflecting an improvement in market conditions and increased investor confidence, with some companies raising their repurchase prices by over 140% [1][6]. Group 1: Companies Adjusting Repurchase Prices - On August 26, companies such as Jinli Permanent Magnet, Jinchun Co., Toukeng Life, and Kesi Technology announced increases in their share repurchase price limits [1]. - Jinli Permanent Magnet raised its repurchase price limit from 31.06 CNY/share to 42.66 CNY/share, an increase of 37.35% [2]. - Jinchun Co. increased its limit from 17.90 CNY/share to 35 CNY/share, marking a 95.53% rise [2]. - Toukeng Life adjusted its limit from 15.85 CNY/share to 29.34 CNY/share, an 85.11% increase [2]. - Kesi Technology raised its limit from 53.86 CNY/share to 102 CNY/share, an increase of 89.38% [2]. Group 2: Market Trends and Implications - The average increase in repurchase prices among the 18 companies is 61.5% [6]. - The rise in repurchase prices is attributed to two main factors: the recovery of the market and the companies' confidence in their future stability and intrinsic value [4][6]. - Companies are utilizing special loans to support their repurchase plans, as seen with Aoshikang, which secured a loan of up to 162 million CNY for its repurchase [8]. Group 3: Regulatory and Market Environment - The Chinese government has encouraged companies to use repurchase and increase strategies to enhance market stability [8]. - Industry experts suggest that companies should carefully evaluate and dynamically adjust their repurchase plans to ensure effective implementation and bolster market confidence [9].

OranutritionLimited56%股权。截至本公告披露之日，公司已完成在山东省商务等主管部门的境外投资备 案及设立香港全资子公司等工作。根据买卖双方签署的《股权收购协议》，本次交易交割的先决条件已 全部满足或被豁免，买卖双方已于2025年8月25日完成交割，公司香港子公司 BiohighOverseasInvestmentLimited已向NZHealthyWealthyLimited支付了相关股权购买价款。本次交易完 成后，Ora将纳入公司合并范围内，以控股子公司的形式进行管理。 （文章来源：证券日报） 证券日报网讯 8月25日晚间，百合股份发布公告称，公司拟使用自有资金1，624万新西兰元（折合人民 币约6，700万元）于香港新设一家全资子公司用于收购NZHealthyWealthyLimited持有的 ...

公司于 2025 年 4 月 14 日召开的第四届董事会第十一次会议审议通过了《关 于拟收购境外公司股权并签署股权收购协议的议案》。根据公司的整体战略规划， 为完善公司海外生产基地布局，加速公司国际化进程，进一步提升公司的核心竞 争力，公司拟使用自有资金 1,624 万新西兰元（折合人民币约 6,700 万元）于香 港新设一家全资子公司用于收购 NZ Healthy Wealthy Limited 持有的 Oranutrition Limited 56%股权。本次交易完成后，Ora 将纳入公司合并范围内，以控股子公司 的形式进行管理。具体内容详见公司于 2025 年 4 月 15 日在巨潮资讯网 （www.cninfo.com.cn）披露的《威海百合生物技术股份有限公司关于拟收购境外 公司股权并签署股权收购协议的公告》（公告编号：2025-017）。 二、进展情况 截至本公告披露之日，公司已完成在山东省商务等主管部门的境外投资备案 及设立香港全资子公司等工作。根据买卖双方签署的《股权收购协议》，本次交 易交割的先决条件已全部满足或被豁免，买卖双方已于 2025 年 8 月 25 日完成交 割，公司香港子公司 ...

Group 1 - The core viewpoint of the news is that Baihe Co., Ltd. has experienced fluctuations in its stock price and trading activity, with a recent decline of 2.13% on August 22, 2023, and a total market capitalization of 2.759 billion yuan [1][2] - Baihe Co., Ltd. has seen a year-to-date stock price increase of 25.43%, with a recent 5-day increase of 1.58%, but a decline of 1.53% over the past 20 days and 1.03% over the past 60 days [2] - The company has appeared on the "Dragon and Tiger List" three times this year, with the most recent appearance on May 20, 2023, showing a net buy of -20.08 million yuan on that day [2] Group 2 - Baihe Co., Ltd. is located in Rongcheng City, Shandong Province, and was established on November 16, 2005, with its stock listed on January 25, 2022 [2] - The company's main business involves nutritional health food, and it belongs to the food and beverage industry, specifically in food processing and health products [2] - As of March 31, 2023, the number of shareholders for Baihe Co., Ltd. was 8,115, an increase of 8.47% from the previous period, while the average circulating shares per person decreased by 7.62% to 4,419 shares [2] - For the first quarter of 2023, Baihe Co., Ltd. achieved operating revenue of 207 million yuan, a year-on-year increase of 9.75%, and reported a net profit attributable to the parent company [2] - Since its A-share listing, Baihe Co., Ltd. has distributed a total of 164 million yuan in dividends, with 132 million yuan distributed over the past three years [2]

Summary of Key Points Core Viewpoint - On August 15, a total of 9 companies had their restricted shares unlocked, with a total unlock volume of 158 million shares, amounting to a market value of 5.146 billion yuan at the latest closing price [1] Group 1: Unlock Volume and Market Value - The unlock volume of 4 companies exceeded 10 million shares [1] - The companies with the highest unlock volumes were Zhimi Intelligent (44 million shares), Kunheng Shunwei (36.3084 million shares), and Rongfa Nuclear Power (32.1003 million shares) [1] - In terms of unlock market value, 4 companies had unlock values exceeding 100 million yuan [1] Group 2: Companies with High Unlock Ratios - The companies with the highest unlock market values were Zhimi Intelligent (2.371 billion yuan), Baihe Co. (1.193 billion yuan), and Kunheng Shunwei (1.054 billion yuan) [1] - Three companies had an unlock ratio exceeding 10% of their total share capital [1] - The companies with the highest unlock ratios were Baihe Co. (43.96%), Kunheng Shunwei (29.81%), and Zhimi Intelligent (17.47%) [1]

Group 1 - As of August 11, 2025, the stock price of Baihe Co., Ltd. is 43.42 yuan, with a decrease of 0.06 yuan, representing a decline of 0.14% from the previous trading day [1] - The trading volume on the same day was 10,426 hands, with a transaction amount of 0.45 billion yuan [1] - In the first quarter of 2025, the company achieved operating revenue of 207 million yuan and a net profit attributable to shareholders of 35.21 million yuan [1] Group 2 - A total of 28.14 million restricted shares will be released for circulation on August 15, 2025, accounting for 43.96% of the company's total share capital [1] - The release involves two shareholders, including the controlling shareholder and actual controller Liu Xinli and supervisor Liu Zhaomin [1] Group 3 - On August 11, 2025, the net outflow of main funds was 4.95 million yuan, with a cumulative net outflow of 15.19 million yuan over the past five trading days [1]

本次上市流通的限售股为公司首次公开发行限售股，共计 28,135,545 股，占 公司总股本的 43.96%，共涉及 2 名股东，限售股锁定期为自公司股票上市之日 起 36 个月，由于公司股票上市后六个月内，连续二十个交易日的收盘价均低于 发行价，锁定期限自动延长六个月，该部分限售股将于 2025 年 8 月 15 日上市流 通。 二、本次限售股形成至今公司股本数量变化情况 广发证券股份有限公司 关于威海百合生物技术股份有限公司首次公开发行部分限售股 上市流通的核查意见 广发证券股份有限公司（以下简称"广发证券"或"保荐机构"）作为威海 百合生物技术股份有限公司（以下简称"百合股份"或"公司"）首次公开发行 股票并上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交 易所股票上市规则》《上海证券交易所上市公司自律监管指引第 11 号—持续督 导》等相关法律法规的要求，对百合股份首次公开发行部分限售股上市流通的事 项进行了核查，核查情况如下： 一、本次限售股上市类型 经中国证券监督管理委员会（以下简称"中国证监会"）《关于核准威海百 合生物技术股份有限公司首次公开发行股票的批复》（证监许可〔2022 ...

证券日报网讯8月11日晚间，百合股份（603102）发布关于首次公开发行部分限售股上市流通的公告 称，公司本次股票上市类型为首发股份；股票认购方式为网下，本次股票上市流通总数为28，135，545 股。本次股票上市流通日期为2025年8月15日。 ...